AF
FECW

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

		Application Number	09/420,692
		Filing Date	October 19, 1999
		First Named Inventor	BESTERMAN
		Art Unit	1635
		Examiner Name	Zara, Jane J.
Total Number of Pages in This Submission	3	Attorney Docket Number	MET-015US1 (1002/016)

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer		
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application			
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			
Remarks			
1. Post Card			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Wayne A. Keown, Ph.D., Reg. No. 33,923
Signature	
Date	9/21/04

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date: 9/22/04		
Typed or printed	Melanie Legare	Date
Signature		9/22/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Besterman
Serial No.: 09/420,692
Filed: October 19, 1999
Entitled: MODULATION OF GENE EXPRESSION BY COMBINATION THERAPY
Examiner: Zara, Jane J.
Group Art Unit: 1635
Attorney Docket No.: MET-015US1 (1002/016)

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO FINAL OFFICE ACTION

Sir:

In response to the Final Office Action dated August 24, 2004, please consider the following remarks.

Claims 1-3, 6 and 13 are pending in the application. All claims are rejected as not satisfying the written description and enablement requirements. However, these rejections are contrary to both Federal circuit precedent and PTO policy as stated in the M.P.E.P.


As to other oligonucleotides and protein inhibitors, undoubtedly some screening using the method of Example 6 would be required. However, these experiments, which would require no modification of the method of Example 6, would not be undue. The fact that experimentation may be complex does not necessarily make it undue, if the art typically engages in such experimentation. *Massachusetts Institute of Technology v. A.B. Fortia*, 227 U.S.P.Q. 428 (Fed. Cir. 1985) See also M.P.E.P. §2164.01. In the antisense and protein inhibitors fields, scientists typically engage in such screening, and would have to do so no matter how many oligonucleotides or protein inhibitors are exemplified. In addition, the enablement requirement is met if the description enables any mode of making and using the invention. *Johns Hopkins*

University v. Cell Pro Inc., 47 U.S.P.Q.2d 1705, 1718 (Fed. Cir. 1998), *citing Engel Indus., Inc. v. Lockformer Co.*, 20 U.S.P.Q.2d 1300, 1304 (Fed. Cir. 1991). Applicant has clearly met this requirement.

Applicants' invention is not a particular antisense oligonucleotide or a particular DNA MTase protein inhibitor. Rather, it is the discovery that inhibition of DNA MTase gene expression and protein inhibition is synergistic. Accordingly, the rejection of the pending claims for lack of written description and non-enablement was in error.

In view of this precedent and policy, Applicants respectfully request reconsideration of the presently maintained rejections.

Respectfully submitted,



Wayne A. Keown, Ph.D.
Registration No. 33,923

Keown & Associates

500 West Cummings Park - Suite 1200
Woburn, MA 01801
781-938-1805 (Telephone)
781-938-4777 (Facsimile)

9/21/04